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istamine, Mast
ells, and Heart Failure
s There a Connection?*
ary S. Francis, MD, FACC,
. H. Wilson Tang, MD, FACC
leveland, Ohio
e have known about histamine receptors in the heart for
any years (1). The human H1- and H2-histamine recep-
ors were cloned and characterized in the early 1990s (2,3),
ollowed closely by the human H3- and H4-histamine
eceptors several years later (4,5). Histamine is a natural
ody constituent that is found throughout the body, espe-
ially the central nervous system, mast cells, gastric mucosa
arietal cells, and basophils. The H1-receptor is coupled to
-q11 and activates a number of intracellular signals,
ncluding cyclic adenosine monophosphate (cAMP) and
yclic guanosine monophosphate. In the heart, histamine
ecreases atrioventricular node conduction time via H1-
eceptors. The H2-histamine receptors are also found in the
eart, and couple to Gs proteins to signal through cAMP
o produce chronotropic and inotropic activity. The H2-
istamine receptors also subserve hypotension, flushing,
eadache, increased gastric acid production, and enhanced
ascular permeability. Therefore, in essence, histamine is a
rue neurohormone.
See page 1378
Mast cells are found in the heart, where they are known
o release histamine (6). Mast cells and histamine release
ave been implicated in heart disease (7,8), including the
evelopment of heart failure (9). Mast cells, in addition to
istamine, seem to be a unique source of renin (10), and
hus in some cases might contribute to local activation of the
enin-angiotensin-aldosterone system (RAAS) in the heart,
nd all of the potential adverse consequences of that particular
eurohormonal system. Using an isolated Langendorff prepa-
ation, Mackins et al. (11) have shown that cardiac mast
ell-derived renin promotes local angiotensin formation, nor-
pinephrine release, and arrhythmias in an ischemic/
eperfusion model. Mast cell stabilization with cromolyn or
odoxamide attenuates this process (11).
It is bad enough that mast cells release renin and drive the
ocal RAAS, although we have therapy to vitiate the
ownstream responses. The release of histamine from mast
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thei
merican College of Cardiology.
From the Cleveland Clinic, Cleveland, Ohio.ells is another matter. Histamine is present in high con-
entrations in the human heart (12,13). Mast cells have
een shown to be increased in myocardial hypertrophy (14),
known important component of myocardial remodeling
nd heart failure (15). The H2-histamine receptors are
specially a potential problem, because they are linked to
lassic Gs proteins and the production of cAMP, similar to
orepinephrine and beta-adrenergic receptors. In animal
tudies, famotidine and cimetidine (H2-histamine receptor
lockers) attenuate ischemia-induced increases in myocar-
ial cAMP accumulation (16). In principle, H2-histamine
eceptor activation in the heart has the potential to drive
AMP much in the same fashion as excessive norepineph-
ine. If so, pharmacologic blockade of H2-histamine recep-
ors ought to benefit the heart failure syndrome beyond
lockade of the sympathetic nervous system and the RAAS.
t must be remembered that despite our many successes in
he treatment of heart failure, our current drug regimens
robably prolong survival only about 9 to 18 months relative
o where we were in 1985. We still need better therapies,
specially those without significant hemodynamic adverse
ffects.
In this issue of the Journal, Kim et al. (17) reported their
ndings after taking advantage of an interesting technique—
ata mining for discovering useful information hidden in a
atabase, a ploy used by chemical, financial, and insurance
ompanies and similar to the concept of microarray analysis
or genetic discoveries (18). This specific technique is rarely
sed in the medical field, in part because it necessitates
ccurate, complete, and consistent data entry. The analysis
ound that famotidine and proton pump inhibitors extend
eneficial effects in patients with heart failure (18). From
his point, they constructed the hypothesis that H2-
istamine receptor blockade may benefit patients with heart
ailure, and validated it retrospectively in a case-controlled
tudy comparing H2-histamine receptor blockade versus
eprenone (an antiulcer drug independent of H2-histamine
eceptor blockade). The investigators further tested the hy-
othesis prospectively in a small group of patients already
reated with RAAS and beta-adrenergic blocking drugs (18).
For investigators using the cumbersome tool of large
linical trials to find beneficial new drugs, the road has been
ifficult. The annualized mortality for heart failure has
ropped from 18% to 20% to about 6% to 8% on average. In
rinciple, adding a drug such as famotidine allows for
locking a “hidden” neurohormonal target (H2-histamine
eceptor) that may be playing a role in the pathophysiology
f some patients with heart failure. At the end of the day,
urther reduction in cAMP by any mechanism may provide
dditional benefit for patients with heart failure, especially
hose intolerant to beta-adrenergic blockers or taking insuf-
cient doses of beta-adrenergic blockers.
Articles such as this by Kim et al. (17) serve a useful but
ncommon purpose. They introduce new ideas, fresh think-
ng, and alternative considerations. The concept of data
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Editorial Comment October 3, 2006:1385–6ining is familiar to clinical investigators and outcomes
esearchers to uncover adverse drug effects, but the novel
echnique that this group used to uncover a pharmacologic
arget has not been used widely in the medical field. Any
iscoveries and hypotheses generated from data mining
echniques should mandate: 1) the assurance of the reliabil-
ty and completeness of the data that are being analyzed; 2)
he scientific background understanding and the plausibility
f the observations; 3) the availability of a comparably
ensible competing hypothesis (i.e., null hypothesis) that
ay fare worse; and 4) the possibility of such a hypothesis to
e tested prospectively in mechanistic studies, in particular
o show the proposed mechanism(s). Clearly, the prelimi-
ary but provocative findings from years of work by Kim
t al. (17) fulfill this discovery track. These data are unlikely
eproducible in some existing administrative or pharmaceu-
ical claims databases, particularly when data completeness
nd reliability may be questionable.
The H2-histamine receptor blockers are widely used, and
re available over the counter. The rationale for using
2-histamine receptor blockers to treat patients with heart
ailure is relatively straightforward. However, we do not
now what the quantitative contribution of mast cells is to
he syndrome of heart failure. We need to find out more
bout the interactions between histamine, mast cells, and
he heart failure syndrome. The safety and efficacy of this
rug class in the broad heart failure population are yet to be
stablished. The results reported by Kim et al. (17) have to
e validated, and no one is recommending famotidine or any
ther histamine receptor blockers to treat patients with
eart failure based simply on the existing information.
learly, this interesting concept is very early in its develop-
ent, and additional data regarding its efficacy and safety
re required. However, we need some new and imaginative
hinking in this arena, and perhaps this article will serve to
rovide that.
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esk F15, Cleveland, Ohio 44195. E-mail: francig@ccf.org.EFERENCES
1. Eckel L, Gristwood RW, Nawrath H, Owen DA, Satter P. Inotropic
and electrophysiological effects of histamine on human ventricular
heart muscle. J Physiol 1982;330:111–23.
2. Gantz I, Schaffer M, DelValle J, et al. Molecular cloning of a gene
encoding the histamine H2 receptor. Proc Natl Acad Sci U S A
1991;88:5937.
3. Le Coniat M, Traiffort E, Ruat M, Arrang JM, Berger R. Chromo-
somal localization of the human histamine H1-receptor gene. Hum
Genet 1994;94:186–8.
4. Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional
expression of the human histamine H3 receptor. Mol Pharmacol
1999;55:1101–7.
5. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular
cloning and characterization of a novel type of histamine receptor
preferentially expressed in leukocytes. J Biol Chem 2000;275:36781–6.
6. Dvorak AM. Mast-cell degranulation in human hearts. N Engl J Med
1986;315:969–70.
7. Bristow MR, Ginsburg R, Harrison DC. Histamine and the human
heart: the other receptor system. Am J Cardiol 1982;49:249–51.
8. Marone G, de Crescenzo G, Adt M, Patella V, Arbustini E, Genovese
A. Immunological characterization and functional importance of
human heart mast cells. Immunopharmacology 1995;31:1–18.
9. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells
in the evolution to congestive heart failure. J Exp Med 2002;195:375–81.
0. Silver RB, Reid AC, Mackins CJ, et al. Mast cells: a unique source of
renin. Proc Natl Acad Sci U S A 2004;101:13607–12.
1. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin
promotes local angiotensin formation, norepinephrine release, and
arrhythmias in ischemia/reperfusion. J Clin Invest 2006;116:1063–70.
2. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of
Pharmacology. XIII. Classification of histamine receptors. Pharmacol
Rev 1997;49:253–78.
3. Wolff AA, Levi R. Histamine and cardiac arrhythmias. Circ Res
1986;58:1–16.
4. Panizo A, Mindan FJ, Galindo MF, Cenarruzabeitia E, Hernandez
M, Diez J. Are mast cells involved in hypertensive heart disease?
J Hypertens 1995;13:1201–8.
5. Greenberg B, editor. Cardiac Remodeling: Mechanisms and Treat-
ment. 1st edition. New York, NY: Taylor and Francis Group, 2006.
6. Asanuma H, Minamino T, Ogai A, et al. Blockade of histamine H(2)
receptors protects the heart against ischemia and reperfusion injury in
dogs. J Mol Cell Cardiol 2006;40:666–74.
7. Kim J, Ogai A, Nakatani S, et al. Impact of blockade of histamine H2
receptors on chronic heart failure revealed by retrospective and
prospective randomized studies. J Am Coll Cardiol 2006;48:1378–84.
8. Kim J, Washio T, Yamagishi M, et al. A novel data mining approach
to the identification of effective drugs or combinations for targeted
endpoints—application to chronic heart failure as a new form of
evidence-based medicine. Cardiovasc Drugs Ther 2004;18:483–9.
